CSPC Innovation Pharmaceutical Co (300765.SZ) Stock Price

CSPC Innovation Pharmaceutical Co Price

SZSE·CLOSED
34.36
​
Market closed

Over the last 11 years CSPC Innovation Pharmaceutical Co grew revenue by 11.5% annually, reaching 2.15 B CNY. Earnings per share have declined at 6.8% per year over the last 10 years. For CSPC Innovation Pharmaceutical Co, the net margin of -11.2% is down versus 21.3% a few years ago. At today's price the dividend yield works out to roughly 0.06%. The consensus 12-month price target for CSPC Innovation Pharmaceutical Co is 57.83 CNY, about 68.3% above where the stock trades today. Of 7 analysts, 5 rate the stock a buy — an overall Buy consensus.

CSPC Innovation Pharmaceutical Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CSPC Innovation Pharmaceutical Co business model & stock analysis

CSPC Innovation Pharmaceutical Co., Ltd. generates revenue through the manufacturing and sale of active pharmaceutical ingredients and food additives, primarily caffeine and vitamin C products. The company's main products include caffeine, which encompasses small amounts of theophylline, aminophylline, and theobromine, as well as vitamin C tablets and vitamin C drinks. Domestic and overseas markets are the primary distribution channels for these products, with caffeine-based items forming a significant portion of the product portfolio. The firm targets both pharmaceutical and food industries, supplying ingredients for functional foods and medications. The company's caffeine products are sold to manufacturers of pharmaceuticals and food additives, while vitamin C tablets and drinks are distributed to consumers and businesses in the health and wellness sector. The business model relies on producing high-quality active ingredients for global markets, with a focus on caffeine and vitamin C as core offerings. CSPC Innovation Pharmaceutical's product range caters to both domestic and international clients seeking reliable sources of these essential compounds. CSPC Innovation Pharmaceutical Co., Ltd. operates with a clear focus on caffeine and vitamin C as key revenue drivers, leveraging its manufacturing capabilities to serve the pharmaceutical and food additive industries. The firm's domestic market presence complements its overseas sales, ensuring a diversified customer base across multiple regions. By specializing in these specific active ingredients, the company maintains a steady demand from clients requiring standardized, high-purity compounds for their products.

Frequently asked questions about CSPC Innovation Pharmaceutical Co

Analysts currently set an average price target of 57.83 CNY for the CSPC Innovation Pharmaceutical Co stock (median: 57.83 CNY), implying +77.0 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the CSPC Innovation Pharmaceutical Co stock: 5 recommend buying, 2 holding and 0 selling. For 2026, analysts expect CSPC Innovation Pharmaceutical Co to generate revenue of 4.90 B CNY and earnings per share of 0.86 CNY.

Converted at the current exchange rate, the CSPC Innovation Pharmaceutical Co share trades at 4.68 EUR (34.36 CNY).

The CSPC Innovation Pharmaceutical Co share (300765.SZ) is listed on 1 stock exchanges, including: Shenzhen (300765.SZ).

The expected revenue of CSPC Innovation Pharmaceutical Co is 4.90 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of CSPC Innovation Pharmaceutical Co is 1.19 B CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of CSPC Innovation Pharmaceutical Co is currently 40.09. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CSPC Innovation Pharmaceutical Co stock.

The price-to-sales ratio (P/S) of CSPC Innovation Pharmaceutical Co is currently 9.77. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CSPC Innovation Pharmaceutical Co stock.

The Eulerpool Quality Score for CSPC Innovation Pharmaceutical Co is 4/10.

The ISIN of CSPC Innovation Pharmaceutical Co is CNE100003K04. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of CSPC Innovation Pharmaceutical Co is 300765.SZ. The ticker symbol is used to trade CSPC Innovation Pharmaceutical Co shares on the stock exchange.

Fair ValueTerminal
28.86 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
1.10 M CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
Mar 22, 2019
ISIN
CNE100003K04
Cusip
Y1825N103
Market capitalization
48.07 B CNYLarge Cap
52-Week Range
PEG
13.66
P/E ratio
P/Ee 2026
40.28
P/Ee 2027
161.07
P/Ee 2028
64.51
P/Se
9.77
EV/EBIT
—
P/B Ratio
18.02
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-9.02 %
Dividend
Dividend yield
0.06 %
Est. Dividend Yield
0.06 %
Payout Ratio
-11.55 %
Dividend growth Ø5Y
-10.89 %
Dividend payments per year
1
Dividend paid since
6 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
10.00 %
Last updated Nov 17, 2026, 3:40 AM

CSPC Innovation Pharmaceutical Co Peer Group

CSPC Innovation Pharmaceutical Co Ticker

SHZ · 300765.SZ

CSPC Innovation Pharmaceutical Co FIGI

300765:CH · BBG002NBJDJ6300765:CS · BBG00JNJNND1300765:C2 · BBG00R2FQX85